QUECTEL-WIRELESS
10.11.2022 10:01:40 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, announces that its industrial-grade 5G NR module RG500L-EU has gained GCF certification for operating on global 5G NR networks. The GCF certification means that the RG500L-EU module can help customers to efficiently deploy their 5G high-speed IoT devices worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109006142/en/
Quectel, a global IoT solutions provider, announces GCF certification for it's industrial-grade 5G NR module RG500L-EU (Photo: Business Wire)
Based upon the MediaTek T750 platform, the RG500L-EU integrates a 5G NR FR1 modem and a quadcore Arm Cortex-A55 processor. By leveraging the powerful CPU performance of the T750 chipset, customer devices can improve their device processing performance as well as enable significant cost optimization.
“The global certification by the GCF confirms our commitment to provide our customers with best-in-class IoT solutions, no matter where they are in the world,” said Dominikus Hierl, Senior Vice President Sales EMEA. “Quectel continues to drive IoT innovation, providing the very best in 5G modules and delivering the innovation our customers have come to expect in order to develop their 5G IoT applications.”
The module supports dual carrier aggregation (2CC CA) at 200MHz frequency band. This capability to combine available 5G spectrum assets can greatly improve signal coverage and transmission rates. Additionally, the RG500L-EU module can achieve a peak downlink rate of 4.67Gbps and a peak uplink rate of 1.25Gbps, bringing smooth and super-fast 5G speed experience to end users.
The RG500L-EU supports EasyMesh™ and WPA3 R3 encryption protocol, enabling IoT devices with more stable, cost-efficient and secure wireless connections. The module also offers flexible Wi-Fi configuration combinations, including single 5G 2x2 + 2.4G 2x2 dual-band, single 5G 4x4 + single 2.4G 4x4 dual-band, as well as single 5G 4x4 (5G high frequency band) + single 5G 4x4 (5G low frequency band) + single 2.4G 4x4 tri-band.
Featuring a compact design and low power consumption, the RG500L-EU can help customers to reduce time-consuming procedures including fixed network and equipment installation. Its rich peripheral interfaces including SGMII, PCIe and PCM give customers maximum flexibility in their IoT solution designs. In combination with Quectel’s unique QuecOpen platform, the RG500L-EU also improves customer terminal development efficiency and accelerates their time-to-market.
The RG500L-EU adopts an 8-antenna solution with four 2.7GHz antennas and four n77/n78 dedicated antennas to provide terminals with stronger and more stable signals as well as higher peak download rates. The module can additionally provide high gain antenna covering n78 band to help with signal reception.
In addition to the GCF certification, Quectel's 5G module RG500L-EU has also passed CE approval for the EU market as well as RCM approval for the Australian region. In the above areas, Quectel’s RG500L-EU module has already been chosen by customers to develop a variety of terminals including mobile hotspots, customer premise equipment (CPE), outdoor unit (ODU) and other 5G converged gateways and industrial gateways, which have been deployed in areas like industrial monitoring, remote collaboration, video conferencing, telemedicine, online education and many other fields.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109006142/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom